Loading clinical trials...

The Role of Epigenetics in Inner City Asthma | Clinical Trials | Clareo Health

COMPLETED

The Role of Epigenetics in Inner City Asthma

The Role of Epigenetics in Inner City Asthma (ICAC-15)

NCT01382836•National Institute of Allergy and Infectious Diseases (NIAID)

Summary

As part of ongoing efforts to determine the causes of asthma and the progression of the disease, this study will gather data to explore the interaction of genetic and environmental factors in the cause and severity of asthma in inner city children.

Detailed Description

Asthma is a complex, heritable disease that affects more than 11.2% of the U.S. population, which represents approximately 9 million children and 23 million adults. It is thought that asthma may be caused by the interaction of multiple genetic factors, such as whether a parent or sibling has asthma, and environmental factors, such as living in an inner city. Studying DNA from people who have asthma and those who do not have asthma may help us better understand the importance of those genes and how they are involved in asthma severity and response to treatment.

Eligibility

Age

6 - 12 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Black inner city children with or without asthma.
•Control Subjects:
•Black males and females ages 6 to 12 years, inclusive, at Recruitment;
•Who do not have a diagnosis of asthma by a physician;
•Who do not have a diagnosis of atopic dermatitis by a physician;
•Who have an FEV1 ≥ 85% predicted;
•With no positive prick skin-tests to any of a panel of indoor and outdoor allergens;
•With no current asthma as determined by the Respiratory Health Questionnaire (RHQ);
•With no current chronic rhinitis/sinusitis as determined by the RHQ;
•Whose primary place of residence is in one of the pre-selected recruitment census tracts that contains at least 15% of households below the U.S. government poverty level;
+24 more criteria

Exclusion Criteria

•Who have a sibling already enrolled in the study (i.e. one individual from each family is permitted to participate \[case or control\], though samples will be collected from parents and siblings);
•Who have received systemic prednisone (or equivalent) during the 30 days prior to the screening visit;
•Who have received systemic prednisone (or equivalent) for \> 15 days out of the past 60 days prior to the screening visit;
•Who are pregnant or lactating;
•With acute sinusitis, chest infection, or ear infection that required treatment with antibiotics within 30 days of the screening visit;
•Who are currently participating in another asthma-related pharmaceutical study or intervention study or who have participated in another asthma-related pharmaceutical study or intervention study in the month prior to the screening visit;
•Who are currently receiving or have received hyposensitization therapy to any allergen in the past year prior to the screening visit;
•Who have the presence of the following chronic medical conditions: cardiac condition requiring daily medication, seizure disorder requiring daily medication, obvious severe mental retardation that prohibits the subject from answering questions or following instructions, cystic fibrosis, immune deficiency, diabetes, allergic bronchopulmonary aspergillosis, or any other chronic medical condition at the discretion of the study physician. (Exceptions: Attention deficit disorder with or without hyperactivity; iron deficiency anemia; gastroesophageal reflux disease; otitis media (ear infections); sinusitis; allergic rhinitis);
•Who do not speak and understand English;
•Whose caretaker does not speak and understand English.

Locations (6)

National Jewish Health

Denver, Colorado, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

Boston University School of Medicine

Boston, Massachusetts, United States

Henry Ford Health System

Detroit, Michigan, United States

Columbia University Medical Center

New York, New York, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Key Dates

Start Date

January 1, 2011

Primary Completion Date

July 1, 2011

Completion Date

July 1, 2011

Last Updated

November 6, 2015

Enrollment

200

ACTUAL participants

Conditions

Asthma

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 6, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Role of Epigenetics in Inner City Asthma

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma